About us
About us
Vision & Mission
Our Team
Join Us
Service & Tech
Product Development Strategy
Medical Device Testing
Quality System
Clinical Evaluation Report
Clinical Trial
Regulatory Affairs
IVD
Global Reach
News
Company news
Industry news
Contact Us
简
|
EN
About us
About us
Vision & Mission
Our Team
Join Us
Service & Tech
Product Development Strategy
Medical Device Testing
Quality System
Clinical Evaluation Report
Clinical Trial
Regulatory Affairs
IVD
Global Reach
News
Company news
Industry news
Contact Us
中
News
Company news
Industry news
2026
05.28
Tigermed-Jyton Supports Approval of China's First 360-Degree Rotational Proton Therapy System
2026
05.25
Tigermed-Jyton Supports Approval of First PCL Product for Temporal Region
2026
05.25
Tigermed-Jyton Supports China NMPA Approval of Hi-Energy Ultrarapy™
2026
04.28
Officially Released!China’s First Group Standard for Injectable Collagen in Skin Quality Evaluation – Tigermed-Jyton as Key Developer
2026
04.03
Tigermed-Jyton supports China NMPA Approval of Retoxin® ——The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A
2026
04.01
Tigermed-Jyton supports China NMPA Approval of Respacio® ——The First lsolation Hydrogel for Cervical Cancer Radiotherapy In The Word
2025
09.25
Tigermed-Jyton Supports the Multi-center Clinical Registration Study of the First Modular General Microsurgical Robot in China
2025
09.24
Womed Leaf, US’s First-in-Class degradable film for treating intrauterine adhesion received approval by FDA, Tigermed-Jyton CRO service made great contribution
2025
07.07
Tigermed Supports FDA Clearance of Fasikl’s Felix™ NeuroAI™ Wristband —the First AI-Powered Wearable Approved for Essential Tremor
2025
05.13
Tigermed-Jyton Supports the Approval of the First Hyaluronic Acid Sodium Composite Solution in the China Market.
Home
Prev
1
2
Next
End
TOP
Contacts
Cookies
The site uses cookies in order to collect data to provide general statistics to optimize site functionality and offer you a better experience. For more information,
visit our Privacy Policy.
Reject All
Accept All